{"entity":{"id":"nct07104266","kind":"trial","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","aka":[],"tldr":"A phase 2 trial of celecoxib in triple-negative breast cancer, run by Université de Sherbrooke, now recruiting.","summary":"Triple Negative Breast Cancer and Celecoxib. Pilot Study is a phase 2, randomised interventional study registered as NCT07104266 by Université de Sherbrooke, with a registry enrolment figure of 30 participants, started 2025-08-04 and due to reach its primary completion in 2028-08-04. Interventions recorded: Celecoxib (Celebrex); Placebo. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* TNBC status confirmed by pathology\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07104266","url":"https://clinicaltrials.gov/study/NCT07104266"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":["celecoxib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07104266","phase":"2","setting":"Determine Whether Administering Celecoxib During Radiotherapy Can Reduce the Risk of Recurrence of Triple-negative Breast Cancer. Pilot Study","sponsor":"Université de Sherbrooke","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07104266/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"drug":[{"id":"celecoxib","kind":"drug","name":"Celecoxib","route":"/drugs/celecoxib/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}